Market revenue in 2023 | USD 0.1 million |
Market revenue in 2030 | USD 1.8 million |
Growth rate | 46.3% (CAGR from 2023 to 2030) |
Largest segment | C.difficle |
Fastest growing segment | C.difficle |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Brazil live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil holds a major share of the live biotherapeutic products and microbiome CDMO market in Latin America and is expected to maintain its dominance over the forecast period. Among the Latin American countries, the clinical trials are mostly conducted in Brazil owing to its cost-effectiveness, high prevalence of diseases, and ease of patient recruitment.
Due to the rapidly growing demand for LBP products, there is a rising number of trials being conducted in this region, which is expected to drive market growth during the forecast period. Increasing R&D capabilities and initiatives among global companies are likely to attract investments from pharmaceutical and biotech companies.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Brazil live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account